@entity2742 associated with relatively low 1:25 XXXX levels post-renal transplant can be successfully treated with oral @entity3873 .

@entity1 @entity500 @entity229 @entity3873 @entity205 @entity79 @entity1011 @entity3151 @entity2742 @entity461 @entity560
Since endogenous 1:25 @entity560 (1:25VD) is principally involved with involution of secondary @entity2742 post-renal transplant we correlated 1:25VD levels with intact @entity461 in 82 random @entity1 with a serum @entity1011 of < 2 mg/dl and with normal hepatic function. All @entity1 studied were normocalcemic with normal @entity3151 and received @entity500 , @entity205 and @entity229 . Of considerable interest, of the 42 @entity1 studied after 2 years post-transplant, there were 8 (19%) @entity1 with intact @entity461 of more than twice the upper limit of normal (normal 10-65 pg/ml) and other 15 (36%) with @entity461 levels above normal. Secondly, in no @entity1 did we see 1:25VD above normal (normal 15-60 pg/ml) despite levels of @entity461 of > 200 pg/ml. Of concern, 20% of 73 @entity1 had 1:25VD deficiency (< 15 pg/ml). This may not have been previously appreciated because of the number of @entity1 studied. Like previous investigators, we failed to understand why 1:25VD levels were relatively low. There was no correlation between 1:25VD and serum @entity1011 . Of 25 @entity1 with a serum @entity1011 of 1.4 or less, there were 10 @entity1 (40%) with 1:25VD of less than 20 pg/ml. Since persistently high @entity461 can contribute to @entity79 , which is not uncommon post-transplant, we treated 8 @entity1 with small doses of oral 1:25VD ( @entity3873 ). In less than 6 months @entity461 levels returned to normal in 7 of the 8 @entity1 . The current studies clearly indicate that asymptomatic @entity2742 is common even after 2 years post-renal transplant. Monitoring for @entity461 and 1:25VD will help prevent @entity79 post-transplant now that @entity3873 is available.
